Showing 6461-6470 of 9245 results for "".
Can Treating Atopic Dermatitis Restore Growth in Children?
https://practicaldermatology.com/programs/practical-dermatology-type-ii-inflammation-journal-club/can-treating-atopic-dermatitis-restore-growth-in-children/50933/Practical Dermatology Editorial Board members Natasha Mesinkovska, MD, PhD, and Christopher Bunick, MD, FAAD, discuss the Journal of the American Academy of Dermatology article “Dupilumab, atopic dermatitis, and linear growth: Navigating beyond association to mechanism and intervention,” which featuConnections for the Future of Dermatology
https://practicaldermatology.com/videos/skin-minute/connections-for-the-future-of-dermatology/54688/Frederick Beddingfield, MD, PhD, recaps the Dermatology Summit 2026, a meeting to connect innovators and investors in the field of dermatology.Ensuring Equity for Your Patients
https://practicaldermatology.com/podcasts/the-practical-dermatology-podcast/ensuring-equity-for-your-patients/54335/Jeanine Downie, MD, FAAD, and an expert panel discuss implicit bias and discrimination against various marginalized populations and how to be proactive in avoiding these problems in your practice. Joining Dr. Downie are Drs. Mona Gohara, Anthony Rossi, Jacob Beer, and Jane Yoo. This discussion is baDWTV Extra: Rocatinlimab Trials
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-rocatinlimab-trials/39044/Clinical investigator Emma Guttman-Yassky, MD, PhD, discusses two sets of data presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. The phase 3 ROCKET-Ignite Trial evaluated the efficacy and safety of OX40-receptor targeting with rocatinlimab in moderate-to-severe aDWTV Extra: Remembering Dr. Robert Sidbury
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-remembering-dr-robert-sidbury/36520/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD; Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD; and Board Member Peter A. Lio, MD, FAAD, reflect on the life and career of their colleague Robert Sidbury, MD, MPH, who passed away suddenly at the age of 61.Evaluating Lebrikizumab in Pigmented Skin
https://practicaldermatology.com/videos/updates-atopic-dermatitis/evaluating-lebrikizumab-in-pigmented-skin/36490/Andrew Alexis, MD, MPH, discusses new data presented at the Revolutionizing Atopic Dermatitis (RAD) Conference from the phase 3b Admirable trial, the first dedicated study for evaluating the efficacy and safety of Lilly's FDA-approved medicine in adult and adolescent patients with pigmented skin andDWTV Extra: Image-Guided SRT Consensus
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-image-guided-srt-consensus/35744/Jacob Scott, MD, chairman of the Dermatology Association of Radiation Therapy (DART), discusses an expert panel's recommendations on the role of image-guided superficial radiation therapy in the treatment of non melanoma skin cancer, which were published in an article titled "The Role of Image-GuideLong-Term Bimzelx Data Presented
https://practicaldermatology.com/videos/dermwire-tv/long-term-bimzelx-data-presented/35563/In this week's DermwireTV, new long-term data is presented for Bimzelx (bimekizumab-bkzx) for two indications; an analysis examines the correlation between proximity to tanning facilities and melanoma incidence; and in our C-Suite Chats feature, we hear from the Founder and CEO of Joya Health.DWTV Extra: New Tapinarof Data for AD
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-new-tapinarof-data-for-ad/33940/Linda Stein Gold, MD, discusses the results from the Phase 3 ADORING 3 open-label, long-term extension study evaluating tapinarof cream, 1% once daily in children as young as 2 and adults with atopic dermatitis, presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in OrlandoStep Therapy Reform Advocates Seek to Spread Awareness of Proposed Law
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/step-therapy-reform-advocates-seek-to-spread-awareness-of-proposed-law/33160/The Safe Step Act would stop insurance companies under certain circumstances from requiring alternative medications before covering biologics.